Check-Cap Ltd. (MBAI)
Develops a swallowable capsule that detects precancerous polyps in the colon.
$1.03-0.04%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago+52.1%
The outlook
Check-Cap trades at $1.03, well below both its 50- and 200-day moving averages, and sits near the bottom of its 52-week range. Analyst coverage appears thin, and the overall sentiment leans bearish. The stock's valuation metrics and price position reflect significant weakness in the current trend.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range13% of the way from its 52-week low to high
Market cap
$8.0M
52-wk high
$3.92
52-wk low
$0.59
50-day avg
$1.37
200-day avg
$1.61
Trailing P/E
1.6